TARRYTOWN, NY, July 11 28, 2022 (GLOBE NEWSWIRE) — Prestige Consumer Healthcare Inc. (NYSE: PBH) announced today that it will report its first quarter fiscal 2023 results on Thursday, August 4, 2022 before market open. The Company will host a conference call to discuss the results that morning at 8:30 a.m. ET.
To participate in the live webcast over the Internet, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call by phone, listeners calling from the United States and Canada can dial 833-634-2598 or 412-902-4108 internationally and join the Prestige earnings call. Consumer Healthcare.
A replay of the conference call will be available for approximately one week after the live call ends and can be accessed on the company’s Investor Relations page or at 877-344-7529 in the United States, 855-669 -9658 in Canada and 412-317 -0088 internationally using the conference ID is 9498360.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to points of sale in the United States and Canada, Australia and certain other international markets. The Company’s diversified brand portfolio includes Monistat® and the eve of summer® women’s health products, BC® and Goody’s® painkillers, clear eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® glycerin enemas and suppositories, Chloraseptic® and Luden’s® Sore Throat Treatments and Drops Compound W® Wart Treatments, Small Remedies® over-the-counter pediatric products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada and Hydralyte® rehydration products and Fess® range of nose and sinus care products in Australia. Visit the Company’s website at www.prestigeconsumerhealthcare.com.
Phil Terpolilli, CFA, 914-524-6819